CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and ...
Topline results from Phase 2 EMBRAZE proof-of-concept trial in adult patients with obesity on track for June 2025 Cash, cash equivalents and marketable securities of $364.4 million as of March 31, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results